New drug developments in metastatic gastric cancer

被引：19

作者：

Tan, Aaron C. ^{[2
,3
]}

Chan, David L. ^{[2
,4
]}

Faisal, Wasek ^{[5
]}

Pavlakis, Nick ^{[1
]}

机构：

[1] Royal North Shore Hosp, Northern Sydney Canc Ctr, Reserve Rd, St Leonards, NSW 2065, Australia

[2] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia

[3] Natl Canc Ctr, Singapore, Singapore

[4] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia

[5] Ballarat Reg Integrated Canc Ctr, Ballarat, Vic, Australia

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2018年 / 11卷

关键词：

gastric cancer; immunotherapy; targeted therapy; GASTROESOPHAGEAL JUNCTION CANCER; RANDOMIZED PHASE-II; DOUBLE-BLIND; 1ST-LINE THERAPY; OPEN-LABEL; PLUS PACLITAXEL; ADENOCARCINOMA; CAPECITABINE; CHEMOTHERAPY; MET;

D O I：

10.1177/1756284818808072

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.

引用

页数：13

共 89 条

[31] Genetic Activation of the MET Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer [J].

Graziano, Francesco ;

Galluccio, Nadia ;

Lorenzini, Paola ;

Ruzzo, Annamaria ;

Canestrari, Emanuele ;

D'Emidio, Silvia ;

Catalano, Vincenzo ;

Sisti, Valerio ;

Ligorio, Claudia ;

Andreoni, Francesca ;

Rulli, Eliana ;

Di Oto, Enrico ;

Fiorentini, Giammaria ;

Zingaretti, Costantino ;

De Nictolis, Michele ;

Cappuzzo, Federico ;

Magnani, Mauro .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) :4789-4795

[32] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[33] Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial [J].

Hecht, J. Randolph ;

Bang, Yung-Jue ;

Qin, Shukui K. ;

Chung, Hyun C. ;

Xu, Jianming M. ;

Park, Joon O. ;

Jeziorski, Krzysztof ;

Shparyk, Yaroslav ;

Hoff, Paulo M. ;

Sobrero, Alberto ;

Salman, Pamela ;

Li, Jin ;

Protsenko, Svetlana A. ;

Wainberg, Zev A. ;

Buyse, Marc ;

Afenjar, Karen ;

Houe, Vincent ;

Garcia, Agathe ;

Kaneko, Tomomi ;

Huang, Yingjie ;

Khan-Wasti, Saba ;

Santillana, Sergio ;

Press, Michael F. ;

Slamon, Dennis .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) :443-+

[34] HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. [J].

Hofheinz, Ralf ;

Hegewisch-Becker, Susanna ;

Thuss-Patience, Peter C. ;

Kunzmann, Volker ;

Fuchs, Martin ;

Graeven, Ullrich ;

Homann, Nils ;

Heinemann, Volker ;

Pohl, Michael ;

Tannapfel, Andrea ;

Al-Batran, Salah-Eddin .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[35] Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies [J].

Iacovelli, Roberto ;

Pietrantonio, Filippo ;

Farcomeni, Alessio ;

Maggi, Claudia ;

Palazzo, Antonella ;

Ricchini, Francesca ;

de Braud, Filippo ;

Di Bartolomeo, Maria .

PLOS ONE, 2014, 9 (09)

[36] Clinical significance of MET in gastric cancer [J].

Inokuchi, Mikito ;

Otsuki, Sho ;

Fujimori, Yoshitaka ;

Sato, Yuya ;

Nakagawa, Masatoshi ;

Kojima, Kazuyuki .

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (11) :317-327

[37] Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study [J].

Iveson, Timothy ;

Donehower, Ross C. ;

Davidenko, Irina ;

Tjulandin, Sergey ;

Deptala, Andrzej ;

Harrison, Mark ;

Nirni, Somanath ;

Lakshmaiah, Kuntegowdanahalli ;

Thomas, Anne ;

Jiang, Yizhou ;

Zhu, Min ;

Tang, Rui ;

Anderson, Abraham ;

Dubey, Sarita ;

Oliner, Kelly S. ;

Loh, Elwyn .

LANCET ONCOLOGY, 2014, 15 (09) :1007-1018

[38]

IWASA S, 2018, J CLIN ONCOL S, V36

[39] Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step? [J].

Janjigian, Yelena Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) :401-+

[40] MET Expression and Amplification in Patients with Localized Gastric Cancer [J].

Janjigian, Yelena Y. ;

Tang, Laura H. ;

Coit, Daniel G. ;

Kelsen, David P. ;

Francone, Todd D. ;

Weiser, Martin R. ;

Jhanwar, Suresh C. ;

Shah, Manish A. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (05) :1021-1027

← 1 2 3 4 5 6 7 8 9 →